Mark J. Niciu
Affiliations: | Yale University, New Haven, CT |
Area:
Addiction Psychiatry, Psychiatric Co-Morbidity, Copper Biology, NeuropeptideGoogle:
"Mark Niciu"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Niciu MJ, Meisner RC, Carr BR, et al. (2023) National network of depression centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder. Journal of Affective Disorders |
| Alario AA, Niciu MJ. (2022) (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy. Chronic Stress (Thousand Oaks, Calif.). 6: 24705470221128017 |
| Alario AA, Niciu MJ. (2021) Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology. Chronic Stress (Thousand Oaks, Calif.). 5: 24705470211014210 |
| Ballard ED, Vande Voort JL, Bernert RA, et al. (2019) Correction. Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder The Journal of Clinical Psychiatry. 77: e1655 |
| Johnson IN, Shovestul BJ, Niciu MJ, et al. (2019) 1.60 ANTIDEPRESSANT TREATMENT OF MDD IN PATIENTS WITH COMORBID ALCOHOL USE DISORDER: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS WITH DISCUSSION OF PEDIATRIC IMPLICATIONS Journal of the American Academy of Child & Adolescent Psychiatry. 58: S166 |
| Richards EM, Zanotti-Fregonara P, Fujita M, et al. (2018) PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. Ejnmmi Research. 8: 57 |
| Kadriu B, Yuan S, Farmer C, et al. (2018) Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. Journal of Clinical Psychopharmacology |
| Niciu MJ, Shovestul BJ, Jaso BA, et al. (2018) Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. Journal of Affective Disorders. 232: 310-315 |
| Ballard ED, Yarrington JS, Farmer CA, et al. (2018) Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. Journal of Affective Disorders. 231: 51-57 |
| Niciu MJ, Iadarola ND, Banerjee D, et al. (2017) The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. Journal of Psychopharmacology (Oxford, England). 269881117732514 |